• research
• publications

Recent Publications

• Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009 Dec;27(12):2875-83.
• del Carmen MG, Findley Muzikansky MA, Roche M, Verrill CL, Horowitz N, Seiden MV. A comparison of demographics, risk factors, and screening knowledge between Latino and non-Latino women referred for colposcopy. Gynecol Oncol. 2007;104:70-76.
• Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009 Jun;123(6):1262-7.e1.
• Seiden MV. (Editor). Progress in gynecologic cancer. Semin Oncol. 2009;36:90.
• Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res. 2008 May 15;14(10):3193-203. Accepted prior to April 7, 2008
• Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H, Seiden MV. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol. 2009 Mar;63(4):681-9. Epub 2008 Jun 28.
• van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm. 2008 Jul-Aug;5(4):516-26. Epub 2008 Jul 11.
• Growden WB, Lopez-Varela E, Littell R, Oliva E, Seiden M, Krasner C, Lee H, Fuller A. Extent of extracranial disease is a powerful predictor of survival in patients with brain metastases from gynecologic cancer. Int J Gynecol Cancer. 2008;18:262-268. Accepted prior to April 7, 2008
• Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10. Epub 2008 Feb 19.
• Sakamoto H, Friel AM, Wood AW, Guo L, Ilic A, Seiden MV, Chung DC, Lynch MP, Serikawa T, Munro E, Oliva E, Orsulic S, Kirley SD, Foster R, Zukerberg LR, Rueda BR. Mechanisms of cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther. 2008 Feb;7(2):180-88. Epub 2007 Nov 15.
• Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med. 2007 Dec 12;5:66.
• Berkenblit A, Eder JP Jr, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG. Phase I clinical trial of STA-4783 in combination with Paclitaxel in patients with refractory solid tumors. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):584-90.
• Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007 Nov;72(5):1137-45. Epub 2007 Aug 3.
• Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer. 2007 Oct 15;121(8):1830-8.
• Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, Epenetos AA, Massuger LF. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer. 2007 Jun 15;120(12):2710-4.
• van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. Cancer Res. 2007 May 15;67(10):4843-50.
• Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in patients with platinum resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 2007 Mar;104(3):727-31. Epub 2006 Nov 28.
• Skates SJ, Horick NK, Moy JM, Minihan AM, Seiden MV, Marks JR, Sluss P, Cramer DW. Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41.
• van Vlerken, L.E., Duan, Z., Seiden, M.V., Mansoor, M., Amiji, M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multi-drug resistance in tumor cells. Cancer Res. 67:4843-4850, 2007.
• Seiden MV, Patel D, O'Neill MJ, Oliva E. Case Reports of the MGH. N Engl J Med. 2007;356:1760-1769.
• van Vlerken, L.E., Duan, Z., Seiden, M.V., Mansoor, M., Amiji, M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multi-drug resistance in tumor cells. Cancer Res. 67:4843-4850, 2007.